New hope for advanced colon cancer: drug duo targets tumors
NCT ID NCT07355764
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug combination (SHR-1811 plus bevacizumab) as a second-line treatment for people with metastatic colorectal cancer that has worsened after initial therapy. About 80 adults aged 18-75 will participate. The goal is to see if the combo shrinks tumors and delays cancer growth.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIBODY-DRUG CONJUGATES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can two immune boosters outsmart Chemo-Resistant colon cancer?
- Can a Two-Pronged attack shrink Hard-to-Treat colorectal tumors?
- Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?
- Can a four-drug cocktail shrink hard-to-treat colorectal cancer?
- Can a Drug-Radiation combo outsmart Treatment-Resistant colorectal cancer?
- Can a cholesterol drug help immunotherapy fight colorectal cancer?